Schedule-dependent synergistic interaction between gemcitabine and oxaliplatin in human gallbladder adenocarcinoma cell lines

Anti-Cancer Drugs

Volumn 20, Issue 2, 2009, Pages 123-130

  Makiyama, Akitaka ^a   Qin, Baoli ^a   Uchino, Keita ^a   Shibata, Yoshihiro ^a   Arita, Shuji ^a   Isobe, Taichi ^a   Hirano, Gen ^a   Kusaba, Hitoshi ^a   Baba, Eishi ^a   Akashi, Koichi ^a   Nakano, Shuji ^a,b  

^a KYUSHU UNIVERSITY   (Japan)

^b NAKAMURA GAKUEN UNIVERSITY   (Japan)

Author keywords

Drug interaction; Gallbladder cancer; Gemcrtabine; Oxaliplatin; Schedule dependence

Indexed keywords

GEMCITABINE; OXALIPLATIN;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ANTAGONISM; DRUG POTENTIATION; FLOW CYTOMETRY; GALLBLADDER CARCINOMA; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; PRIORITY JOURNAL;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL COUNT; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; DEOXYCYTIDINE; DRUG SYNERGISM; GALLBLADDER NEOPLASMS; HUMANS; INHIBITORY CONCENTRATION 50; ORGANOPLATINUM COMPOUNDS; TIME FACTORS;

EID: 59449102811     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3283218080     Document Type: Article

References (28)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58:71-96.
2. Huang P, Chubb S, Hertel LW, Grindey GB, Plunkett W. Action of 2′,2′- difluorodeoxycytidine on DNA synthesis. Cancer Res 1991; 51:6110-6117.
3. Ruiz van Haperen VW, Veerman G, Vermorken JB, Peters GJ. 2′,2′-Difluoro- deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumor cell lines. Biochem Pharmacol 1993; 46:762-766.
4. Hertel LW, Boder GB, Kroin JS, Rinzel SM, Poore GA, Todd GC, et al. Evaluation of the antitumor activity of gemcitabine (2′,2′- difluoro-2′- deoxycytidine). Cancer Res 1990; 50:4417-4422.
5. Pasetto LM, D'Andrea MR, Falci C, Monfardini S. Gemcitabine in advanced biliary tract cancers. Crit Rev Oncol Hematol 2007; 61:230-242.
6. Jennerwein MM, Eastman A, Khokhar A. Characterization of adducts produced in DNA by isomeric 1,2-diaminocyclohexane platinum(ll) complexes. Chem Biol Interact 1989; 70:39-49.
7. Dunn TA, Schmoll HJ, Grünwald V, Bokemeyer C, Casper J. Comparative cytotoxicity of oxaliplatin and cisplatin in non-seminomatous germ cell cancer cell lines. Invest New Drugs 1997; 15:109-114.
8. Fukuda M, Ohe Y, Kanzawa F, Oka M, Hara K, Saijo N. Evaluation of novel platinum complexes, inhibitors of topoisomerase I and II in non-small cell lung cancer (NSCLC) sublines resistant to cisplatin. Anticancer Res 1995; 15:393-398.
9. Androulakis N, Aravantinos G, Syrigos K, Polyzos A, Ziras N, Tselepatiotis E, et al. Oxaliplatin as first-line treatment in inoperable biliary tract carcinoma: a multicenter phase II study. Oncology 2006; 70:280-284.
10. Heinemann V, Labianca R, Hinke A, Louvet C. Increased survival using platinum analogue combined with gemcitabine as compared to single-agent gemcitabine in advanced pancreatic cancer: pooled analysis of two randomized trials, the GERCOR/GISCAD intergroup study and a German multicenter study. Ann Oncol 2007; 18:1652-1659.
11. Andre T, Tournigand C, Rosmorduc O, Provent S, Maindrault-Goebel F, Avenin D, et al. Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. Ann Oncol 2004; 15:1339-1343.
12. Harder J, Riecken B, Kummer O, Lohrmann C, Otto F, Usadel H, et al. Outpatient chemotherapy with gemcitabine and oxaliplatin in patients with biliary tract cancer. Br J Cancer 2006; 95:848-852.
13. Faivre S, Raymond E, Woynarowski JM, Cvitkovic E. Supraadditive effect of 2′,2′-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines. Cancer Chemother Pharmacol 1999; 44:117-123.
14. Nakano S, Tatsumoto T, Esaki T, Nakamura M, Baba E, Kimura A, et al. Characterization of a newly established human gallbladder carcinoma cell line. In Vitro Cell Dev Biol 1994; 30A:729-732.
15. Homma S, Hasumura S, Nagamori S, Kameda H. Establishment and characterization of a human gallbladder carcinoma cell line NOZ. Hum cell 1988; 1:95-97.
16. Shimura H, Date K, Matsumoto K, Nakamura T, Tanaka M. Induction of invasive growth in a gallbladder cancer cell line by hepatocyte growth factor in vitro. Jpn J Cancer Res 1995; 86:662-669.
17. Koyama S, Yoshioka T, Mizushima A, Kawakita I, Yamagata S, Fukutomi H, et al. Establishment of a cell line (G-415) from a human gallbladder carcinoma. Gann 1980; 71:574-575.
18. Ishiyama M, Shiga M, Sasamoto K, Mizogichi M, He P. A new sulfonated tetrazolium salt that produces a highly water-soluble formazan dye. Chem Pharm Bull 1993; 41:1118-11 22.
19. Kern W, Braess J, Böttger B, Kaufmann CC, Hiddemann W, Schleyer E. Oxaliplatin pharmacokinetics during a four-hour infusion. Clin Cancer Res 1999; 5:761-765.
20. Takimoto CH, Remick SC, Sharma S, Mani S, Ramanathan RK, Doroshow J, et al. Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study. J Clin Oncol 2003; 21:2664-2672.
21. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22:27-55.
22. Chou TC, Motzer RJ, Tong Y, Bosl GJ. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst 1994; 86:1517-1524.
23. Fujie Y, Yamamoto H, Ngan CY, Takagi A, Hayashi T, Suzuki R, et al. Oxaliplatin, a potent inhibitor of survivin, enhances paclitaxel-induced apoptosis and mitotic catastrophe in colon cancer cells. Jpn J Clin Oncol 2005; 35:453-463.
24. Abbruzzese JL, Frost P. Studies on the mechanism of the synergistic interaction between 2′-deoxy-5-azacytidine and cisplatin. Cancer Chemother Pharmacol 1992; 30:31-36.
25. Yang LY, Li L, Jiang H, Shen Y, Plunkett W. Expression of ERCC1 antisense RNA abrogates gemicitabine-mediated cytotoxic synergism with cisplatin in human colon tumor cells defective in mismatch repair but proficient in nucleotide excision repair. Clin Cancer Res 2000; 6:773-781.
26. Achanta G, Pelicano H, Feng L, Plunkett W, Huang P. Interaction of p53 and DNA-PK in response to nucleoside analogues: potential role as a sensor complex for DNA damage. Cancer Res 2001; 61:8723-8729.
27. Jiang X, Galettis P, Links M, Mitchell PL, McLachlan AJ. Population pharmacokinetics of gemcitabine and its metabolite in patients with cancer: effect of oxaliplatin and infusion rate. Br J Clin Pharmacol 2008; 65:326-333.
28. Louvet C, Labianca R, Hmmel P, Liedo G, Zampino MG, Andre T, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of GERCOR and GISCAD phase III trial. J Clin Oncol 2005; 23:3509-3516.